openPR Logo
Press release

Primary Biliary Cholangitis Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers

11-12-2024 01:40 PM CET | Health & Medicine

Press release from: DelveInsight Business Research LLP

Primary Biliary Cholangitis Pipeline

Primary Biliary Cholangitis Pipeline

DelveInsight's, "Primary Biliary Cholangitis Pipeline Insight 2024" report provides comprehensive insights about 18+ companies and 20+ pipeline drugs in Primary Biliary Cholangitis pipeline landscape. It covers the Primary Biliary Cholangitis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Primary Biliary Cholangitis therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in Primary Biliary Cholangitis Research. Learn more about our innovative pipeline today! @ Primary Biliary Cholangitis Pipeline Outlook- https://www.delveinsight.com/sample-request/primary-biliary-cholangitis-pbc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Primary Biliary Cholangitis Pipeline Report
• In November 2024:- GlaxoSmithKline- This is an open-label, non-comparator, global, multi-center, long-term safety study for evaluating safety and tolerability of linerixibat in participants with cholestatic pruritus in primary biliary cholangitis (PBC) who participated in a prior clinical trial with linerixibat (BAT117123 [NCT01899703], 201000 GLIMMER [NCT02966834] (group 1) or 212620 GLISTEN [NCT00210418]) (group 2). All participants will receive open-label linerixibat for the duration of the study. The study duration is expected to last until the study's end or until linerixibat can be lawfully made available to participants.
• In November 2024:- Mirum Pharmaceuticals Inc.- A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Volixibat in the Treatment of Cholestatic Pruritus in Patients With Primary Biliary Cholangitis. The purpose of this clinical research study is to learn more about the use of the study medicine, volixibat, for the treatment of pruritus (itching) associated with Primary Biliary Cholangitis (PBC), and to assess the possible impact on the disease progression of PBC.
• In November 2024:- Intercept Pharmaceuticals- A Phase 2, Double-Blind, Randomized, Parallel Group Study Evaluating the Efficacy, Safety, and Tolerability of Obeticholic Acid Administered in Combination with Bezafibrate in Subjects with Primary Biliary Cholangitis Who Had an Inadequate Response or Who Were Unable to Tolerate Ursodeoxycholic Acid.
• DelveInsight's Primary Biliary Cholangitis pipeline report depicts a robust space with 18+ active players working to develop 20+ pipeline therapies for Primary Biliary Cholangitis treatment.
• The leading Primary Biliary Cholangitis Companies such as Genfit, Zydus Discovery, Ohara Pharmaceutical, Chia Tai Tianqing Pharmaceutical Group Co. Ltd., Novartis, CymaBay Therapeutics, and others.
• Promising Primary Biliary Cholangitis Therapies such as Saroglitazar Magnesium 1 mg, Seladelpar 10 mg, Obeticholic Acid Tablets, and others.

Stay informed about the cutting-edge advancements in Primary Biliary Cholangitis Treatments. Download for updates and be a part of the revolution in cancer care @ Primary Biliary Cholangitis Clinical Trials Assessment- https://www.delveinsight.com/sample-request/primary-biliary-cholangitis-pbc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Primary Biliary Cholangitis Emerging Drugs Profile
• Elafibranor: Genfit
Elafibranor is a dual agonist of the PPARα and PPARδ. Meaning the drug candidate acts simultaneously on the two nuclear receptors, which both play an important role in numerous processes involved in the development of NASH and its co-morbidities. It has shown highly significant results in its Phase 2 Study in patients with primary biliary cholangitis (PBC), while maintaining a favorable tolerability profile and lack of demonstrated safety concerns, paving the way for advancement into phase 3 clinical trial in 2020. It has recently been granted Breakthrough Therapy Designation by the FDA for the treatment of Primary Biliary Cholangitis (PBC) in adults with inadequate response to ursodeoxycholic acid (UDCA), as well as Orphan Drug Designation by the FDA and the EMA (European Medicines Agency).
• ASC42: Gannex Pharma
ASC42 is a novel non-steroidal, selective, potent FXR agonist. It has shown positive results in its Phase I Study in patients with primary biliary cholangitis with no pruritus observed and LDL-C remained within normal range at the human therapeutic dose of 15 mg. The drug is in Phase II stage of its clinical studies for Primary Biliary Cholangitis.
• OP-724: Ohara Pharmaceutical
OP-724 is a synthetic small molecule which is an inhibitor of cyclic AMP response element-binding protein (CREB)-binding protein (CBP)/β-catenin. Ohara Pharmaceutical obtained development rights for OP-724 from PRISM BioLab in 2018 . The drug is in Phase I stage of its clinical studies for Primary Biliary Cholangitis.

Learn more about Primary Biliary Cholangitis Drugs opportunities in our groundbreaking Primary Biliary Cholangitis Research and development projects @ Primary Biliary Cholangitis Unmet Needs- https://www.delveinsight.com/sample-request/primary-biliary-cholangitis-pbc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Primary Biliary Cholangitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Primary Biliary Cholangitis Products have been categorized under various Molecule types such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Discover the latest advancements in Primary Biliary Cholangitis Treatment by visiting our website. Stay informed about how we're transforming the future of oncology @ Primary Biliary Cholangitis Market Drivers and Barriers, and Future Perspectives- https://www.delveinsight.com/sample-request/primary-biliary-cholangitis-pbc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Primary Biliary Cholangitis Pipeline Report
• Coverage- Global
• Primary Biliary Cholangitis Companies- Genfit, Zydus Discovery, Ohara Pharmaceutical, Chia Tai Tianqing Pharmaceutical Group Co. Ltd., Novartis, CymaBay Therapeutics, and others.
• Primary Biliary Cholangitis Therapies- Saroglitazar Magnesium 1 mg, Seladelpar 10 mg, Obeticholic Acid Tablets, and others.
• Primary Biliary Cholangitis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Primary Biliary Cholangitis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of Primary Biliary Cholangitis Pipeline on our website @ Primary Biliary Cholangitis Drugs and Companies- https://www.delveinsight.com/sample-request/primary-biliary-cholangitis-pbc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. Primary Biliary Cholangitis: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Primary Biliary Cholangitis - DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Elafibranor: Genfit
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. ASC42: Gannex Pharma
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. OP-724: Ohara Pharmaceutical
15. Drug profiles in the detailed report…..
16. Inactive Products
17. Primary Biliary Cholangitis Key Companies
18. Primary Biliary Cholangitis Key Products
19. Primary Biliary Cholangitis- Unmet Needs
20. Primary Biliary Cholangitis- Market Drivers and Barriers
21. Primary Biliary Cholangitis- Future Perspectives and Conclusion
22. Primary Biliary Cholangitis Analyst Views
23. Primary Biliary Cholangitis Key Companies
24. Appendix

List of Top Selling Market Research Reports in 2024

cardiac monitoring devices market- https://www.delveinsight.com/report-store/cardiac-monitoring-devices-market
embolotherapy market- https://www.delveinsight.com/report-store/embolotherapy-market
keloid market- https://www.delveinsight.com/report-store/keloid-market
orthopedic power devices market- https://www.delveinsight.com/report-store/orthopedic-power-devices-market
shingles market- https://www.delveinsight.com/report-store/shingles-market
short bowel syndrome market- https://www.delveinsight.com/report-store/short-bowel-syndrome-market
surgical sealant market- https://www.delveinsight.com/report-store/surgical-sealant-and-adhesives-market
testicular neoplasm market- https://www.delveinsight.com/report-store/testicular-cancer-market
dyspepsia market- https://www.delveinsight.com/report-store/dyspepsia-market
liquid biospy for cancer diagnostics market- https://www.delveinsight.com/report-store/liquid-biopsy-in-cancer-diagnostics-market
perennial allergic rhinitis market- https://www.delveinsight.com/report-store/perennial-allergic-rhinitis-market
plaque psoriasis market- https://www.delveinsight.com/report-store/chronic-plaque-psoriasis-market
polycystic ovarian syndrome market- https://www.delveinsight.com/report-store/polycystic-ovarian-syndrome-market
respiratory syncytial virus market- https://www.delveinsight.com/report-store/respiratory-syncytial-virus-rsv-market
sarcopenia market- https://www.delveinsight.com/report-store/sarcopenia-market
smoking cessation and nicotine addiction market- https://www.delveinsight.com/report-store/smoking-cessation-and-nicotine-addiction-market
vascular grafts market- https://www.delveinsight.com/report-store/vascular-grafts-market
brucellosis market- https://www.delveinsight.com/report-store/brucellosis-market
catheter stabilization devices market- https://www.delveinsight.com/report-store/catheter-stabilization-securement-device-market
gene therapy in cns disorder market- https://www.delveinsight.com/report-store/gene-therapy-in-cns-disorder-market
nonalcoholic steatohepatitis market- https://www.delveinsight.com/blog/nonalcoholic-steatohepatitis-nash-highly-epidemic
pelvic organ prolapse market- https://www.delveinsight.com/report-store/pelvic-organ-prolapse-market
pertussis market- https://www.delveinsight.com/report-store/pertussis-market
sglt2 inhibitors market- https://www.delveinsight.com/report-store/sglt2-inhibitors-market
viscosupplementation devices market- https://www.delveinsight.com/report-store/viscosupplementation-devices-market
bacterial meningitis market- https://www.delveinsight.com/report-store/meningococcal-meningitis-market
carcinoid syndrome market- https://www.delveinsight.com/report-store/carcinoid-tumor-market
cxcr inhibitors market- https://www.delveinsight.com/report-store/selective-inhibitor-of-the-cxcr4-chemokine-receptor-market-forecast
endoscopic ultrasound market- https://www.delveinsight.com/report-store/endoscopic-ultrasound-market
hdac inhibitors market- https://www.delveinsight.com/report-store/hdac-inhibitors-market
myeloproliferative neoplasms market- https://www.delveinsight.com/report-store/myeloproliferative-neoplasms-market
plasmodium vivax malaria market- https://www.delveinsight.com/report-store/plasmodium-vivax-malaria-market
vascular access devices market- https://www.delveinsight.com/report-store/vascular-access-device-market
venous ulcer market- https://www.delveinsight.com/report-store/venous-leg-ulcer-market
ventral hernia market- https://www.delveinsight.com/report-store/hernia-repair-devices-market
vitreoretinal surgery devices market- https://www.delveinsight.com/report-store/vitreoretinal-surgery-devices-market
wound healing devices market- https://www.delveinsight.com/report-store/wound-healing-devices-market
novel drug delivery devices market- https://www.delveinsight.com/report-store/novel-drug-delivery-devices
phototherapies for psoriasis market- https://www.delveinsight.com/report-store/phototherapies-for-psoriasis-market
pulmonary emphysema market- https://www.delveinsight.com/report-store/chronic-obstructive-pulmonary-disease-copd-market
urea cycle disorders market- https://www.delveinsight.com/blog/urea-cycle-disorder-market
overactive bladder syndrome market- https://www.delveinsight.com/report-store/overactive-bladder-market
pipeline assessment services- https://www.delveinsight.com/consulting/pipeline-assessment-services
somatotropin deficiency market- https://www.delveinsight.com/report-store/somatotropin-deficiency-market
thrombectomy devices market- https://www.delveinsight.com/report-store/thrombectomy-devices-market
tourette syndrome market- https://www.delveinsight.com/report-store/tourette-syndrome-market
external defibrillators market- https://www.delveinsight.com/report-store/defibrillator-market
plantar fasciitis market- https://www.delveinsight.com/report-store/plantar-fasciitis-market
scoliosis market- https://www.delveinsight.com/report-store/scoliosis-market
tendonitis market- https://www.delveinsight.com/report-store/tendonitis-market
urinary catheters market- https://www.delveinsight.com/report-store/urinary-catheters-market
lice infestations market- https://www.delveinsight.com/report-store/lice-infestations-market
peripheral nerve injuries market- https://www.delveinsight.com/report-store/peripheral-nerve-repair-devices-market
sepsis market- https://www.delveinsight.com/report-store/sepsis-market
stem cell market- https://www.delveinsight.com/report-store/stem-cell-market
varicose vein treatment devices market- https://www.delveinsight.com/report-store/varicose-vein-treatment-devices-market
chronic neuropathic pain market- https://www.delveinsight.com/report-store/chronic-neuropathic-pain-market
fabry disease market- https://www.delveinsight.com/report-store/fabry-disease-market
consulting solutions- https://www.delveinsight.com/consulting
pacemakers market- https://www.delveinsight.com/report-store/pacemakers-market
positive airway pressure device market- https://www.delveinsight.com/report-store/positive-airway-pressure-device-market
spinal implants market- https://www.delveinsight.com/report-store/spinal-implants-market
transcatheter heart valve replacement devices market- https://www.delveinsight.com/report-store/transcatheter-heart-valve-replacement-devices-market
lymphoedema market- https://www.delveinsight.com/report-store/lymphedema-market
seltorexant drug market- https://www.delveinsight.com/report-store/major-depressive-disorder-market
surgical mask & respirator market- https://www.delveinsight.com/report-store/surgical-mask-respirator-market
meningococcal meningitis market- https://www.delveinsight.com/report-store/meningococcal-meningitis-market
surgical energy instruments market- https://www.delveinsight.com/report-store/surgical-energy-instruments-electrosurgical-devices-market
surgical lasers market- https://www.delveinsight.com/report-store/surgical-lasers-market
TCR therapy market- https://www.delveinsight.com/report-store/t-cell-receptor-tcr-therapy-market
diabetic wound market- https://www.delveinsight.com/report-store/diabetic-foot-ulcers-dfus-market
indwelling catheters market- https://www.delveinsight.com/report-store/indwelling-catheters-market
Nontuberculous Mycobacterial Market- https://www.delveinsight.com/report-store/nontuberculous-mycobacterial-ntm-infections-market
intraocular lens market https://www.delveinsight.com/report-store/intraocular-lens-market
orthopedic splints device market- https://www.delveinsight.com/report-store/orthotic-devices-market
transcatheter treatment market- https://www.delveinsight.com/report-store/transcatheter-heart-valve-replacement-devices-market
antibody drug conjugate market- https://www.delveinsight.com/report-store/antibody-drug-conjugate-market
bone growth stimulator market- https://www.delveinsight.com/report-store/bone-growth-stimulators-market
NK cell therapy market- https://www.delveinsight.com/report-store/nk-cell-therapy-market
competitive benchmarking- https://www.delveinsight.com/consulting/competitive-benchmarking-services
total knee arthroplasty market- https://www.delveinsight.com/report-store/total-knee-arthroplasty-market
microscopy device market- https://www.delveinsight.com/report-store/microscopy-device-market
skin neoplasm market- https://www.delveinsight.com/blog/skin-cancer-treatment-market-and-key-companies
asperger syndrome market- https://www.delveinsight.com/report-store/autism-spectrum-disorder-asd-market

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Primary Biliary Cholangitis Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers here

News-ID: 3730998 • Views:

More Releases from DelveInsight Business Research LLP

Genital Warts Pipeline Insights Report 2025 | DelveInsight
Genital Warts Pipeline Insights Report 2025 | DelveInsight
DelveInsight's, "Genital Warts Pipeline Insight 2025" report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Genital Warts pipeline landscape. It covers the Genital Warts pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore the comprehensive insights by DelveInsight and stay ahead
Traumatic Brain Injury Pipeline Drugs Report 2025 | DelveInsight
Traumatic Brain Injury Pipeline Drugs Report 2025 | DelveInsight
DelveInsight's "Traumatic Brain Injury Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Tthe raumatic Brain Injury pipeline landscape. It covers the Traumatic Brain Injury pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Traumatic Brain Injury pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore
Bone Metastasis Pipeline Assessment Report 2025 | DelveInsight
Bone Metastasis Pipeline Assessment Report 2025 | DelveInsight
DelveInsight's, "Bone Metastases Pipeline Insight, 2025," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Bone Metastases pipeline landscape. It covers the Bone Metastasis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Bone Metastasis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore the comprehensive insights by DelveInsight
Acquired Immunodeficiency Syndrome Treatment Market Size Report 2032 | DelveInsight
Acquired Immunodeficiency Syndrome Treatment Market Size Report 2032 | DelveInsi …
DelveInsight's "Acquired Immunodeficiency Syndrome Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Acquired Immunodeficiency Syndrome, historical and forecasted epidemiology as well as the Acquired Immunodeficiency Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. To Know in detail about the Acquired Immunodeficiency Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Acquired Immunodeficiency Syndrome Market

All 5 Releases


More Releases for Primary

Direct Primary Care Market
Direct Primary Care Market Worth 80.4 Bn 2031- Exclusive Report by InsightAce Analytic Pvt. Ltd. InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Direct Primary Care Market"- By Type (Clinical Services, Telehealth Services, Laboratory Services, Consultative Services), Care Setting (Office-Based DPC Practices, Home-Based DPC Practices, Telehealth-Only DPC Practices, Hybrid DPC Practices), End Users (Individuals, Employers, Small Businesses, Large Corporations, Insurance Companies (offering DPC as
Primary Sclerosing Cholangitis Market
Primary Sclerosing Cholangitis (PSC) is a rare, chronic liver disease characterized by inflammation and scarring of the bile ducts, leading to liver damage and, ultimately, liver failure. The disease progresses slowly and often goes unnoticed in its early stages. Although the exact cause of PSC remains unknown, it is commonly associated with other inflammatory bowel diseases, particularly ulcerative colitis. The management of PSC includes symptom control, slowing disease progression, and
Primary Biliary Cholangitis Treatment Market
Primary Biliary Cholangitis Treatment Market Global Primary Biliary Cholangitis Treatment Market Expected to Reach US$ YY Million by 2030, Growing at a CAGR of YY%: Market Insights and Dynamics The Global Primary Biliary Cholangitis Treatment Market, which reached US$ YY billion in 2022, is anticipated to achieve US$ YY million by 2030, exhibiting a robust CAGR of YY% during the forecast period from 2024 to 2031. Primary Biliary Cholangitis (PBC), formerly known as
Primary Healthcare Conference 2023
3rd World Congress on Primary Healthcare and Medicare Summit Mercure Roma West, Viale degli Eroi di Cefalonia, 301, 00128 Rome, Italy Email primaryhealthcare@pulsusgathering.org On behalf of the Conference Organizing Committee, we would like to invite all of you for the "3rd Word Congress on Primary Healthcare and Medicare", which is going to be held in Rome, Italy on September 21-23, 2023. Primary Healthcare 2023 focuses on the basic theme "To Manifest the Multimorbidity
Primary Lithium Battery (Primary Lithium Batteries) Market Key Companies and Ana …
The global lithium primary batteries market size will grow from $2.83 billion in 2022 to $2.9 billion in 2023 at a compound annual growth rate (CAGR) of 2.5% Global " Primary Lithium Battery (Primary Lithium Batteries) Market" 2022 Reports give a Key study on the industry status of the Primary Lithium Battery (Primary Lithium Batteries) Manufacturer with the specific statistics, meaning, definition, SWOT Analysis, expert opinion, and recent development across
Primary Prevention of Cancer
Primary prevention of cancer aims to prevent the disease before it ever occurs. More than 4 in 10 cancers as well as cancer deaths are linked to modifiable risk factors that can be altered as part of primary cancer prevention. The modifiable risk factors for primary prevention include: 1. Cigarette smoking: Smoking causes almost all cases of lung cancer and accounts for 30% of all cancer deaths. Prevention strategy for this risk